Results 121 to 130 of about 82,628 (226)

Therapeutic Gene Editing: DNA Repair Pathways, Emerging Editors, and Clinical Progress

iNew Medicine, Volume 2, Issue 1, March 2026.
ABSTRACT The field of gene editing has evolved rapidly over the past decade, progressing from programmable zinc‐finger nucleases (ZFNs) and transcription activator‐like effector nucleases (TALENs) to the widespread adoption of CRISPR‐Cas systems. First‐generation editors catalyzed genome engineering by introducing targeted double‐strand breaks (DSBs ...
Li‐Kuang Tsai, Youcai Xiong, Dongqi Liu, Dongshan Yang, Jifeng Zhang, Jie Xu, Renzhi Han, Y. Eugene Chen   +7 more
wiley   +1 more source

CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these ...
Yaoxian Lou, Xiuting He, Guangming Li, Martin Sikhondze, Jianping Ma, Hongwei Du, Xin Ouyang, Gianpietro Dotti, Mohammad Sajadi, Lishan Su   +9 more
wiley   +1 more source

T‐Cell Immunity and Lung Cancer

Respirology, Volume 31, Issue 3, Page 236-249, March 2026.
ABSTRACT Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity.
Kotaro Yamada, Yosuke Togashi
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

Host factors and early treatments to restrict paediatric HIV infection and early disease progression [PDF]

, 2015
open6noA body of evidence indicates that a threshold level of the virus is required to establish systemic and persistent HIV infection in the host and that this level depends on virus-host interactions.
De Rossi, Anita, Freguja, Riccardo, Gianesin, Ketty, Giaquinto, Carlo, Petrara, Raffaella, Zanchetta, Marisa   +5 more
core   +1 more source

Methylmalonic Acid, an Aging‐Associated Metabolite, Accelerates Intervertebral Disc Degeneration by Inducing Disc Vascularization via the CCL7/JAK2‐STAT3/VEGF Signaling Axis

Aging Cell, Volume 25, Issue 3, March 2026.
Our study reveals that elevated MMA in aged intervertebral discs promotes degeneration by activating the CCL7/JAK2‐STAT3/VEGF signaling axis, which drives pathological vascularization. Therapeutically, the VEGFR inhibitor lenvatinib attenuated this process, identifying disc vascularization as a promising therapeutic target for IVDD.
Yuanzhang Jin, Runtian Zhou, Xiaonan Wang, Haifeng Liu, Xiaofeng Zhao, Doudou Jing, Bin Zhao   +6 more
wiley   +1 more source

T‐bet Fate Mapping Reveals Gestational Stage‐Specific Transcriptional Adaptation of Decidual NK Cells

American Journal of Reproductive Immunology, Volume 95, Issue 3, March 2026.
ABSTRACT Problem Natural killer (NK) cells are critical regulators of immune balance at the maternal–fetal interface. T‐bet (Tbx21) is a key transcription factor shaping NK cell effector functions, yet its role in decidual NK (dNK) cell adaptation across gestation remains unclear.
Mona A. Mohamed, Yan Li, Andrea K. Wegrzynowicz, Payton N. Lindner, Jessica Vazquez, Gladys E. Lopez, Aleksandar K. Stanic   +6 more
wiley   +1 more source

Enumeration, Phenotyping, and Clinical Associations of Tissue‐Resident T Cells in the Ecto‐ and Endocervix of Women Attending a Colposcopy Clinic

American Journal of Reproductive Immunology, Volume 95, Issue 3, March 2026.
ABSTRACT Problem Tissue‐resident memory (TRM) cells represent important immune sentinels that mount rapid recall responses to pathogens and cancers. However, there are limited data in humans on genital tract TRM collected by clinically feasible sampling methods, limiting a full understanding of their role in immunity and clinical disease.
Aloysious Ssemaganda, Nyambura Kahia, Myo Minn Oo, Dafne Rozenberg, Faisal Nuhu, Naima Jahan, Fran Mulhall, Karen Downing, Bonnie Sandberg, Heather Elands, Robyn Groff, Alon D. Altman, Christine Robinson, Yoav Keynan, Charles N. Bernstein, Vanessa Poliquin, Janilyn Arsenio, Lyle R. McKinnon   +17 more
wiley   +1 more source

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy

British Journal of Pharmacology, Volume 183, Issue 6, Page 1233-1249, March 2026.
Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley   +1 more source

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

HIV Medicine, Volume 27, Issue 3, Page 386-396, March 2026.
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
M. Gartland, X. Wang, Q. Liao, B. Li, F. Du, M. Krystal, A. R. Tenorio, A. Pierce, J. R. Castillo‐Mancilla   +8 more
wiley   +1 more source